Bayer

News

Ardelyx’s-ambition-to-revolutionise-kidney-treatment

EU clears Bayer's chronic kidney disease drug Kerendia

Bayer has claimed EU approval for Kerendia, its new drug for chronic kidney disease (CKD) in people with type 2 diabetes, as the company tries to build a role of the drug alongside rival th

News

Bayer triples sales forecast for prostate cancer drug Nubeqa

Bayer now says it expects to make €3 billion in sales for its prostate cancer treatment Nubeqa, up from an earlier estimate of €1 billion, after reviewing new data for the drug in metastati

News

Genetic testing hopes to speed up drug development in rare eye diseases

Oxurion reports stronger data for diabetic eye disease drug

Belgian biotech Oxurion has revealed new data from a phase 2 trial of its plasma kallikrein inhibitor THR-149, in development for people with

News

FDA fast tracks Bayer's oral anticoagulant asundexian

The FDA has granted fast-track status to Bayer's oral Factor Xia inhibitor asundexian, which is in phase 2 testing as an anticoagulant that could offer safety advantages over current drugs.

News

Bayer's pipeline takes a hit as it drops eliapixant

Bayer has abandoned development of its investigational P2X3 receptor antagonist eliapixant, despite promising efficacy data in clinical trials, on what appears to be safety grounds.

News